Bayesian deep neural networks for low-cost neurophysiological markers of Alzheimer's disease severity
Authors:
Wolfgang Fruehwirt,
Adam D. Cobb,
Martin Mairhofer,
Leonard Weydemann,
Heinrich Garn,
Reinhold Schmidt,
Thomas Benke,
Peter Dal-Bianco,
Gerhard Ransmayr,
Markus Waser,
Dieter Grossegger,
Pengfei Zhang,
Georg Dorffner,
Stephen Roberts
Abstract:
As societies around the world are ageing, the number of Alzheimer's disease (AD) patients is rapidly increasing. To date, no low-cost, non-invasive biomarkers have been established to advance the objectivization of AD diagnosis and progression assessment. Here, we utilize Bayesian neural networks to develop a multivariate predictor for AD severity using a wide range of quantitative EEG (QEEG) mark…
▽ More
As societies around the world are ageing, the number of Alzheimer's disease (AD) patients is rapidly increasing. To date, no low-cost, non-invasive biomarkers have been established to advance the objectivization of AD diagnosis and progression assessment. Here, we utilize Bayesian neural networks to develop a multivariate predictor for AD severity using a wide range of quantitative EEG (QEEG) markers. The Bayesian treatment of neural networks both automatically controls model complexity and provides a predictive distribution over the target function, giving uncertainty bounds for our regression task. It is therefore well suited to clinical neuroscience, where data sets are typically sparse and practitioners require a precise assessment of the predictive uncertainty. We use data of one of the largest prospective AD EEG trials ever conducted to demonstrate the potential of Bayesian deep learning in this domain, while comparing two distinct Bayesian neural network approaches, i.e., Monte Carlo dropout and Hamiltonian Monte Carlo.
△ Less
Submitted 13 December, 2018; v1 submitted 12 December, 2018;
originally announced December 2018.
Riemannian tangent space mapping and elastic net regularization for cost-effective EEG markers of brain atrophy in Alzheimer's disease
Authors:
Wolfgang Fruehwirt,
Matthias Gerstgrasser,
Pengfei Zhang,
Leonard Weydemann,
Markus Waser,
Reinhold Schmidt,
Thomas Benke,
Peter Dal-Bianco,
Gerhard Ransmayr,
Dieter Grossegger,
Heinrich Garn,
Gareth W. Peters,
Stephen Roberts,
Georg Dorffner
Abstract:
The diagnosis of Alzheimer's disease (AD) in routine clinical practice is most commonly based on subjective clinical interpretations. Quantitative electroencephalography (QEEG) measures have been shown to reflect neurodegenerative processes in AD and might qualify as affordable and thereby widely available markers to facilitate the objectivization of AD assessment. Here, we present a novel framewo…
▽ More
The diagnosis of Alzheimer's disease (AD) in routine clinical practice is most commonly based on subjective clinical interpretations. Quantitative electroencephalography (QEEG) measures have been shown to reflect neurodegenerative processes in AD and might qualify as affordable and thereby widely available markers to facilitate the objectivization of AD assessment. Here, we present a novel framework combining Riemannian tangent space mapping and elastic net regression for the development of brain atrophy markers. While most AD QEEG studies are based on small sample sizes and psychological test scores as outcome measures, here we train and test our models using data of one of the largest prospective EEG AD trials ever conducted, including MRI biomarkers of brain atrophy.
△ Less
Submitted 22 November, 2017;
originally announced November 2017.
